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Abstract Human seminal fluid contains a number of tripeptide 
amides with similar structures to thyrotropin releasing hormone 
(TRH), two of which have been identified as pGlu-Glu-Pro amide 
and pGlu-Pbe-Pro amide. To determine whether these peptides 
originate in the same tissues and have the same molecular origin, 
TRH-immunoreactive peptides were extracted from the prostate 
and testis of the rabbit, purified by ion exchange chromatography 
and HPLC, and identified by co-chromatography with 3H-la- 
belled marker peptides. In addition, trypsin digestion was used to 
release TRH-iike tripeptides from N-extended forms of these 
peptides. The sole TRH-like peptide in the prostate was shown 
to be pGlu-Glu-Pro amide; it was not accompanied by a detecta- 
ble amount of pGhi-Phe-Pro amide. The prostate also appeared 
to contain a very small amount of N-extended forms of these 
peptides. In contrast to the prostate, the testis contained high 
concentrations of N-extended forms of pGlu-Phe-Pro amide but 
essentially no tripeptide. The testis also contained N-extended 
forms of two other neutral TRH-like peptides which were less 
hydrophobic than pGlu-Phe-Pro amide. Neither the prostate nor 
the testis contained a significant amount of TRH. The results 
show that in the rabbit the TRH-like peptides pGlu-Glu-Pro 
amide and pGlu-Phe-Pro amide occur in different tissues and 
appear to be formed from different precursors. 
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I. Introduction 
Initial reports that rat prostate and human seminal fluid 
contain peptides with TRH-immunoreactivity [1,2] led to the 
identification of two novel TRH-l ike tripeptides [3,4]. These 
peptides were related in structure to TRH,  the histidine residue 
at position 2 of the hormone being by replaced by either glu- 
tamic acid or phenylalanine. Since the TRH-l ike peptides were 
present in the seminal fluid, it was anticipated that they might 
be important for fertility. Recently a potent activity was dem- 
onstrated for pGlu-Glu-Pro amide in increasing the capacita- 
tion of sperm [5,6] and this peptide has also been found to 
increase the motility of sperm from certain infertile males [7]. 
Similar studies have yet to be reported with the phenylalanine 
containing tripeptide but the presence of a C-terminal amide 
group in these peptides, a structure possessed by a multiplicity 
of peptide hormones, indicates that the TRH-l ike peptides will 
be found to fulfil physiological functions. 
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When pGlu-Glu-Pro amide and pGlu-Phe-Pro amide were 
isolated from seminal fluid, it was not known whether they 
originated from the same or from different tissues. Further- 
more, since their sequences do not occur in the TRH-pro-  
hormone [8,9], it is clear that these TRH-l ike peptides must be 
formed by the processing of precursors distinct from that of 
TRH. In this communication we present evidence that pGlu- 
Glu-Pro amide and pGlu-Phe-Pro amide originate in different 
tissues and seem likely to be formed from different precursors. 
2. Experimental 
2.1. Dissection and extraction of tissues 
Prostate and testis were removed from a New Zealand White rabbit 
(3.1 kg) immediately after sacrifice. The tissues were frozen at -70°C 
and stored at this temperature until they were extracted. Each tissue 
was weighed and homogenised at 4°C for 3 min in 10 ml of acid acetone 
(40 ml of acetone: 1 ml of concentrated HCI: 5 ml of H20) using an 
Ultra-Turrax homogenizer. To each homogenate was added ~25I-la- 
belled TRH (104 counts, prepared by labelling synthetic TRH with 
[t25I]iodine using the chloramine-T method) together with [3H]pGlu- 
Glu-Pro amide and [3H]pGlu-Phe-Pro amide (approximately 5.103 
counts of each peptide, generously donated by Dr. R. Bilek) which 
served as markers to indicate the elution positions of the corresponding 
endogenous peptides. The 3H-labelled peptides also provided internal 
standards to calculate the recoveries of the endogenous peptides [10]. 
The suspensions were centrifuged at 2.10 4 x g, 4°C for 30 min, the 
supernatant solutions decanted and the solvents removed in vacuo on 
a rotary evaporator. 
2.2. Trypsin digestion of N-extended forms of TRH-like peptides 
The dried tissue extracts were taken up in 10 ml of 50% acetic acid 
and divided into two equal parts, the first for trypsin digestion to release 
TRH-like peptides from their N-extended forms and the second for 
direct RIA to determine the free TRH-like tripeptides. Each fraction 
was evaporated in vacuo. Trypsin digestion was carried out in 2 ml of 
100 mM Tris hydrochloride at pH 8 in the presence of TPCK-trypsin 
(40ill of 1 mg/ml); the digest was incubated at 37°C for 16 h and then 
was maintained at 100°C for 1 h to complete the cyclization of N- 
terminal glutaminyl residues to pyroglutamic acid. The solutions were 
dried in vacuo and the peptides extracted into methanol (5 ml). The 
methanol solution was decanted, the solvent evaporated in vacuo and 
the residual peptides dissolved in 1 ml of 50% acetic acid in preparation 
for mini-column cation exchange chromatography. The remaining half 
of the initial tissue extracts, which would contain free TRH-like tripep- 
tides, was not digested with trypsin but like the trypsin digested fraction 
was purified by methanol extraction prior to mini-column chromatog- 
raphy. 
2.3. Separation of TRH-like peptides from TRH by chromatography on 
cation exchange mini-columns 
Briefly the procedure involved addition of the methanol extracted 
peptide mixtures in 50% acetic acid (0.9 ml) to a mini-column (6 x 0.5 
cm) of SP-Sephadex C25, prepared in the pyridinium form by washing 
with 1 M-HC1 and then successively with H20, 1 M-pyridine, HzO, and 
50% acetic acid (2 ml each). After addition of the sample, the column 
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was eluted in 50% acetic acid (8 x 0.5 ml fractions) and then in 0.4 M 
pyridine in 50% acetic acid (12 x 0.5 ml fractions). Using this method 
each peptide mixture added to the column was divided into 2 fractions, 
the first containing peptides that were neutral or acidic and the second 
peptides that carried a positive charge. Thus TRH was retained uring 
the elution with 50% acetic acid while the TRH-like peptides emerged 
without retention. To confirm the retention of TRH in each application 
of the mini-column, the [~25I]TRH present in each sample was measured 
by ?'-counting of the eluted fractions. Aliquots (50 pl) of each fraction 
were then dried in a vacuum centrifuge (V.A. Howe, Banbury, Oxford- 
shire, UK) and the TRH-like peptides determined by RIA with a TRH- 
antiserum. The TRH-immunoreactive p ptides in the column fractions 
were combined in two groups: non-retained (Fractions 4-8) and re- 
tained (fractions 12-17). The resulting solutions were concentrated in 
vacuo and the residual peptides dissolved in 1 ml of 10 mM-HC1 in 
preparation for HPLC. 
2.4. Resolution of TRH-like peptides by HPLC 
High performance liquid chromatography was carried out on a C 18 
,uBondapak column (0.39 x 30 cm, 10 ~m particle size, Millipore-Wa- 
ters, UK, Watford, Herts., UK) with 10 mM HC1 as the stationary 
phase and methanol as the mobile phase. A linear gradient of 0.5% 
methanol/min was applied during collection of the first 20 fractions (6 
min), after which the gradient was increased to 2%/min for the remain- 
ing 80 fractions (24 min). The flow rate used was 1.5 ml/min. Included 
with the sample added to the HPLC column was 3H-labelled TRH (Du 
Pont Ltd., NEN Products, Stevenage, Herts., UK, 119 mCi//~mol, ap- 
proximately 5x 103 counts) in addition to the two H3-1abelled TRH- 
like peptides that were added to the initial tissue extracts. In this way 
each sample added to the HPLC column included three 3H-labelled 
markers, pGlu-His-Pro amide (TRH), pGlu-Glu-Pro amide, and pGlu- 
Phe-Pro amide. Aliquots (50 ,ul) of each fraction obtained by HPLC 
were removed to locate the 3H-labelled peptide markers; they were 
detected by addition to a scintillation cocktail (4 ml, Ready Safe, Beck- 
man Instruments, USA) before counting on a Beckman LS 7000 instru- 
ment. The endogenous peptides were located and determined by RIA 
with TRH-antiserum after removal of solvent in vacuo. The fractions 
containing each peak of TRH-immunoreactivity were combined. 
2.5. Resolution of acidic J~om neutral and basic TRH-immunoreactive 
peptides by analytical mini-column chromatography onDEA E- 
Sephadex 
Mini-columns (6 × 0.5 cm) were prepared by pouring a suspension 
of DEAE-Sephadex A25 (Pharmacia LKB Biotechnology AB, 
Uppsala, Sweden) in 400 mM sodium phosphate at pH 7.5 and the 
columns were washed with 1 ml of HzO and 2 ml of 20 mM sodium 
phosphate pH 7.5. Aliquots from each TRH-like peptide resolved by 
HPLC were dried in vacuo and the residues dissolved in 1 ml of 20 mM 
sodium phosphate for application to the DEAE-column. Ten fractions 
(0.5 ml) were collected in 20 mM sodium phosphate and a further 10 
fractions were collected in 200 mM sodium phosphate. To detect he 
peptides, aliquots were removed for RIA with TRH-antibody, the salt 
concentration i  each aliquot being adjusted to 200 mM before assay. 
2.6. R1A of TRH-immunoreactive peptides 
The concentrations of TRHolike peptides were determined by RIA 
using a sheep antiserum raised against synthetic TRH [11] and quanti- 
tation was by comparison with a synthetic TRH standard (Peninsula 
Laboratories, St. Helens, Merseyside, UK). The concentrations of the 
peptides are given in terms of synthetic TRH; pGlu-Glu-Pro amide 
possesses approximately 50% of the immunoreactivity of TRH [3] and 
pGlu-Phe-Pro amide is equally reactive [4]. The procedure mployed for 
RIA has been described [12] except hat the separation of bound from 
free ligand was accomplished by using 20% (w/v) polyethylene glycol 
(PEG) in place of activated charcoal. After incubation with antibody, 
100 /11 of heat inactivated horse serum (Flow Laboratories Ltd., 
Uxbridge, Mddx., UK) and 500/11 of 20% PEG (Sigma, St. Louis, MO, 
USA) were added. The suspensions were mixed and centrifuged at 
2 × 103 g for 20 min at 4°C using a Beckman GPR centrifuge. The 
supernatants were removed cautiously and the radioactivity in the pel- 
lets was measured with an LKB ),-counter Model 1282, Pharmacia 
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Fig. 1. Mini-column cation exchange chromatography of TRH-immunoreactive p ptides from rabbit prostate (a) without rypsin digestion, (b) with 
trypsin digestion; and from rabbit testis (c) without rypsin digestion, and (d) with trypsin digestion. The vertical arrow in each figure indicates the 
elution position of [~25I]TRH. 
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Fig. 2. Resolution of TRH-immunoreactive peptides from rabbit pros- 
tate by HPLC (a) without rypsin digestion and (b) with trypsin diges- 
tion. The arrows from L to R mark the elution positions of [3H]pGlu- 
His-Pro amide, [3H]pGlu-Glu-Pro amide, and [3H]pGlu-Phe-Pro 
amide. 
3. Results 
3.1. Determination of TRH-like peptides in rabbit prostate 
The initial purification of TRH-like peptides from rabbit 
prostate (0.73 g) was by methanol extraction and mini-column 
cation exchange chromatography (Fig. la). As shown in Table 
1, more than 90% of the total TRH-immunoreactivity (2.45 
pmol) passed through the mini-column without retention. Thus 
the majority of the TRH-like peptides in the prostate were 
neutral or acidic and little or none of the basic hormone (TRH) 
appeared to be present, in accord with our previous observation 
that mRNA for the TRH-prohormone could not be detected 
in rat prostate [14]. When the trypsin digested extract from the 
prostate was applied to the mini-column (Fig. lb), essentially 
the same result was obtained. This extract would contain TRH- 
like peptides released from N-extended forms in addition to free 
TRH-like tripeptides, but the TRH-immunoreactivity in this 
fraction was found to be marginally less than was observed in 
the extract hat had not been exposed to trypsin. It therefore 
appears that negligible TRH-immunoreactive p ptide was re- 
leased by the digestion with trypsin. The results show that the 
rabbit prostate contained acidic or neutral TRH-like tripep- 
tides (3.17 pmol TRH-immunoreactivity/g) but no significant 
N-extended forms of these peptides. 
Further chromatography of the unretained fraction from the 
cation exchange column was carried out by HPLC (Fig. 2a), 
revealing a single TRH-immunoreactive p ptide. It co-chroma- 
tographed with 3H-labelled pGlu-Glu-Pro amide. The trypsin 
digested peptide mixture, after mini-column chromatography, 
showed a very similar pattern to the non-digested fraction (Fig. 
2b), indicating that little or no N-extended forms of TRH-like 
peptides were present in the prostate. Since the TRH-im- 
munoreactivity of pGlu-Glu-Pro amide was 50% that of TRH, 
the concentration of this peptide in the prostate was calculated 
to be 6.34 pmol/g. As expected, the acidic properties of the 
prostate peptide were confirmed by anion exchange mini-col- 
umn chromatography: the peptide was completely retained on 
DEAE-Sephadex. 
3.2. Determination of TRH-like peptides in rabbit testis" 
The first stage in the purification of TRH-like peptides from 
rabbit testis was carried out in parallel with the purification of 
the prostate peptides, involving methanol extraction and mini- 
column cation exchange chromatography. In the case of the 
extract hat had not been exposed to trypsin, virtually no TRH- 
immunoreactivity was seen in either the non-retained or re- 
tained fractions from the mini-column (Fig. lc). In contrast, 
when the trypsin digested peptides from the testis (1.26 g) were 
fractionated on the mini-column, substantial TRH-im- 
munoreactivity (23 pmol) was observed which was not retained 
on the column; but again very little basic TRH-immunoreactiv- 
ity was seen in the retained fractions (Fig. ld). Since the TRH- 
immunoreactivity was observed only in the trypsin digested 
fraction, it can be attributed to TRH-like peptides released 
from N-terminally extended forms. Further chromatography of 
these peptides, which were not retained on the mini-column, 
was carried out by HPLC. Three clearly resolved peaks of 
TRH-immunoreactivity were seen (Fig. 3), of which the most 
hydrophobic co-chromatographed with [3H]pGlu-Phe-Pro 
amide. These TRH-immunoreactive p ptides were examined by 
anion exchange mini-column chromatography: each of the pep- 
tides passed through the DEAE- column without retention and 
behaved as a neutral peptide. The structure of the two TRH- 
like peptides that were less retained on HPLC than pGlu-Phe- 
Pro amide have not so far been elucidated. 
4. Discussion 
The two TRH-like peptides pGlu-Glu-Pro amide and pGlu- 
Phe-Pro amide have been identified previously in human semen 
[4,15] but since the seminal fluid includes the secretions of a 
number of glands it was not known whether these peptides were 
produced together or whether they originated from different 
tissues. The acidic TRH-like peptide pGlu-Glu-Pro amide was 
first isolated from rabbit prostate [3] and since that time it has 
been shown to occur in the prostate of a number of other 
Table 1 
Determination fTRH, TRH-like peptides and their N-extended forms 
in rabbit prostate and testis by mini-column cation exchange chroma- 
tography 
Tissue Molecular form Non-retained Retained 
(pmol/g) (pmol/g) 
Prostate Tripeptides 3.17 0.25 
Tripeptides + N-extended 2.44 < 0.17 
Testis Tripeptides 0.11 
Tripeptides + N-extended 18.2 0.10 
The tripeptides in the tissue xtracts were determined by TRH-RIA of 
aliquots of the column fractions without rypsin digestion; the N-ex- 
tended forms of the tripeptides in the tissue extracts were digested with 
trypsin prior to chromatography and the released TRH-immunoreac- 
tive peptides together with the endogenous tripeptides were chromato- 
graphed and determined by TRH-RIA. 
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Fig. 3. Chromatography of TRH-immunoreactive peptides released by 
trypsin from N-extended forms present in rabbit estis by HPLC. The 
arrows from L to R mark the elution positions of 3H-labelled marker 
peptides as in Fig. 2. 
species [14,16]. The neutral TRH-like peptide pGlu-Phe-Pro 
amide, on the other hand, was first isolated from human semen; 
it has not been reported to be present in rabbit prostate though 
it does appear to occur as a minor component in rat prostate 
[14] and possibly as a trace component in human prostate [16]. 
It should be mentioned that this peptide appears more promi- 
nent when its presence is revealed by the use of an antibody 
with a higher reactivity for neutral peptides uch as pGlu-Phe- 
Pro amide than for acidic peptides uch as pGlu-Glu-Pro amide 
[14]. In general, however, it is clear that the principal TRH-like 
peptide in the prostate of most species is pGlu-Glu-Pro amide. 
The present experiments confirm that rabbit prostate con- 
tains pGlu-Glu-Pro amide but show that it does not contain a 
detectable amount of pGlu-Phe-Pro amide. The major tissue 
where this peptide was found was the testis; however it occurred 
there exclusively in an N-extended form from which the tripep- 
tide could be released by digestion with trypsin. This would 
indicate that pGlu-Phe-Pro amide is not derived from a precur- 
sor that contains a paired basic residue sequence on the N- 
terminal side of the tripeptide, since this would be expected to 
offer a favourable site for proteolytic processing. It is more 
likely that this tripeptide is preceded in its precursor by a single 
basic residue which would render the precursor sensitive to 
cleavage by trypsin but not to intracellular processing [17]. 
Unlike pGlu-Phe-Pro amide, the acidic peptide pGlu-Glu-Pro 
amide which was present in the prostate and not the testis 
occurred almost exclusively as the tripeptide. This peptide, 
therefore, is likely to be formed by a classical processing mech- 
anism involving cleavage of the precursor at paired basic resi- 
dues followed by removal of the basic amino acids to release 
Gln-Glu-Pro-Gly, reactions that generally go to completion. 
The TRH-like tripeptide pGlu-Glu-Pro amide would be gener- 
ated from the tetrapeptide by cyclisation of its N-terminal glu- 
tamine [18,19] and amidation at the C-terminal glycine [20]. 
That pGlu-Glu-Pro amide and pGlu-Phe-Pro amide were 
present in different issues implies that they are formed from 
different precursors. This conclusion, however, will have to be 
confirmed by identification of the precursor sequences. The 
differential distribution of the two peptides certainly suggests 
that their physiological roles are unlikely to be the same, 
though their activities could prove to be complementary since 
both peptides are present or are generated in the seminal fluid. 
It has been reported that pGlu-Glu-Pro amide can increase the 
capacitation ofmouse sperm [5], with a potential for increasing 
fertility. The interaction of this peptide with sperm in vivo 
would take place when the prostate secretions containing the 
peptide are added to the seminal fluid. On the other hand, the 
neutral TRH-like peptide pGlu-Phe-Pro amide is elaborated 
principally in an N-extended form and it is to be expected that 
this tripeptide would be released from its precursor by the 
action of the trypsin-like nzymes derived from the prostate 
after ejaculation has taken place. This would be consistent with 
the possibility that the tripeptide pGlu-Phe-Pro amide is gener- 
ated over a period of time. Indeed it has been reported that 
incubation of human semen in vitro leads to the progressive 
appearance of a hydrophobic TRH-immunoreactive peptide 
[21]. It is likely that this peptide is pGlu-Phe-Pro amide. 
In conclusion, the main finding of the present study is that 
rabbit prostate contains pGlu-Glu-Pro amide but not pGlu- 
Phe-Pro amide whereas the testis contains an N-extended form 
of pGlu-Phe-Pro amide but no pGlu-Glu-Pro amide. This im- 
plies that the two TRH-like peptides are generated from differ- 
ent precursors and are formed by different processing mecha- 
nisms. 
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